Acetyldigitoxin
生产企业：Novartis pharmaceuticals corp
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
Acetyldigitoxin binds to a site on the extracellular aspect of the α-subunit of the Na/K ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na/K pump leads to increased Na levels, which in turn slows down the extrusion of Ca via the Na/Ca exchange pump. Increased amounts of Ca are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias.
Used for fast digitalization in congestive heart failure.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
